Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Table 4

Safety of patients with expected course of treatment.

Variable	Group		Rivaroxaban (86)	Warfarin (42)		value
Reexamination after 1 month	No bleeding	55	40 (46.51%)	15 (35.71%)	0.7656	0.3816
	Mild bleeding	54	36 (41.86%)	18 (42.86%)	0.0066	0.9350
	Serve bleeding	3	0 (0%)	3 (7.14%)	6.1429	0.0132
	Major bleeding	2	0 (0%)	2 (4.76%)	4.0952	0.0430
	—	14	10 (11.63%)	4 (9.52%)
Reexamination after 3 months	No bleeding	49	38 (44.19%)	11 (26.19%)	2.3872	0.1223
	Mild bleeding	61	40 (46.51%)	21 (50%)	0.0721	0.7884
	Serve bleeding	3	0 (0%)	3 (7.14%)	6.1429	0.0132
	Major bleeding	2	0 (0%)	2 (4.76%)	4.0952	0.0430
	—	13	8 (9.3%)	5 (11.9%)
Reexamination after 6 months	No bleeding	46	37 (43.02%)	9 (21.43%)	3.6617	0.0557
	Mild bleeding	65	41 (47.67%)	24 (57.14%)	0.4982	0.4803
	Serve bleeding	4	1 (1.16%)	3 (7.14%)	3.2292	0.0723
	Major bleeding	3	1 (1.16%)	2 (4.76%)	1.5596	0.2117
	—	10	6 (6.98%)	4 (9.52%)